Kyverna Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDKyverna Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 84), indicating clear outperformance against the broad market. Earnings contraction of 6% provides fundamental context to the price action. Investors should exercise caution due to high volatility (112% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $9.33 | -0.32% | BELOW |
| 50 SMA | $8.84 | +5.19% | ABOVE |
| 100 SMA | $8.64 | +7.62% | ABOVE |
| 150 SMA | $8.13 | +14.46% | ABOVE |
| 200 SMA | $7.14 | +30.26% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is KYTX in an uptrend right now?
KYTX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, KYTX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is KYTX overbought or oversold?
KYTX's RSI (14) is 54. The stock is in neutral territory, neither overbought nor oversold.
Is KYTX outperforming the market?
KYTX has a Relative Strength (RS) Rating of 84 out of 99. Yes, KYTX is a market leader, outperforming 84% of all stocks over the past 12 months.
Where is KYTX in its 52-week range?
KYTX is trading at $9.30, which is 68% of its 52-week high ($13.67) and 63% above its 52-week low ($1.96).
How volatile is KYTX?
KYTX has a Beta of 3.05 and 52-week volatility of 112%. It's more volatile than the S&P 500 - expect bigger swings.